Menu
Explore a research direction
Pharmacology and drug discovery
research labs.
Explore labs that list pharmacology and drug discovery among their research interests, including work on how drugs act and how new therapies are found. Each profile links to its official sources so you can check what a group actually studies before you decide whom to contact.
What to compare
When comparing groups in pharmacology and drug discovery, look at screening, chemistry and computational approaches, and the stage of work from target to preclinical testing. Ask how a new researcher would be involved and what preparation is expected.
Profiles appear here because their listed research keywords match this topic. Inclusion does not establish an open position. Check the official sources and any published application instructions before reaching out.
Prepare a research introduction ↗14 research-led lab profiles
Browse labs by their listed college affiliationBrent Stockwell Research Group
Columbia UniversityBrent Stockwell · Professor of Chemistry
How can small molecules reveal the biochemical mechanisms governing cell death? The research group of Brent Stockwell works at the interface of chemistry and biology, using small organic molecules to perturb cellular processes. His research involves small molecules used to understand and treat cancer and neurodegeneration. The approach is interdisciplinary, combining chemical design and synthesis with genomics, computational chemistry, biochemistry and cell biology. The laboratory is particularly interested in cell death mechanisms in mammalian systems and how they intersect with disease mechanisms in cancer and neurodegeneration.
Carl Nathan Research Group
Cornell UniversityCarl Nathan · Professor
How do macrophages and Mycobacterium tuberculosis interact during infection? Carl Nathan is listed as Professor and Chair of Microbiology & Immunology at Weill Cornell Medical in New York City. The lab studies host pathways controlling susceptibility and resistance to Mtb. The lab also studies the biology of Mtb in non-replicating states. The lab is developing new kinds of antimicrobial molecules to overcome the phenotypic resistance of non-replicating Mtb to most antibiotics.
Jimeng Sun Research Group
University of Illinois at Urbana-ChampaignJimeng Sun · Professor
How can artificial intelligence be used to improve healthcare, from drug discovery and clinical trials to health monitoring and treatment recommendation? Jimeng Sun's research includes deep learning for drug discovery, clinical trial optimization, and computational phenotyping. It also covers clinical predictive modeling, treatment recommendation, and health monitoring. He teaches courses on deep learning for healthcare and AI in medicine. His research interests include data and information systems, bioinformatics and computational biology, and artificial intelligence.
Le Roch Lab
University of California, RiversideKarine Le Roch · Professor of Molecular, Cell and Systems Biology
Malaria parasites depend on carefully regulated gene activity to develop and survive. Le Roch’s laboratory investigates the molecular pathways underlying that biology using functional genomics and drug discovery approaches. Research includes chromatin structure, epigenetic regulation, and long noncoding RNAs in apicomplexan parasites such as Plasmodium falciparum. High throughput methods help identify pathways involved in parasite and host cell development. The group asks how RNA and chromatin regulation work and whether understanding those mechanisms could reveal new therapeutic approaches to parasitic disease.
Michael Sanguinetti Research Group
University of UtahMichael Sanguinetti · Professor in the Division of Cardiology
What are the properties of cardiac ion channels, and what is the molecular basis of inherited arrhythmia? Michael Sanguinetti is a Professor in the Division of Cardiology at the University of Utah. His research laboratory is located at the Nora Eccles Harrison Cardiovascular Research and Training Institute. His research interests include cellular cardiac electrophysiology, ion channel biophysics and pharmacology, and the molecular basis of inherited arrhythmia. He uses biophysical and molecular biological techniques to study the properties of cardiac ion channels.
Paul J. Hergenrother Research Group
University of Illinois at Urbana-ChampaignPaul J. Hergenrother · Professor of Chemistry
Which small organic compounds selectively kill cancer cells or drug-resistant bacteria and by what mechanisms? Hergenrother's group designs, synthesizes, and evaluates organic molecules with novel biological properties, including enzyme modulators and anticancer and antibacterial compounds. Projects include Complexity-to-Diversity (CtD) synthesis of diverse compounds from natural products and high-throughput screening to identify biologically active molecules. Researchers apply structure-based design, medicinal chemistry, and biological assays, including tests on patient samples, to identify personalized anticancer targets such as procaspase-3 activation and NQO1-selective agents. The group develops predictive rules and synthesis strategies to produce compounds active against Gram-negative pathogens.
Peter Wipf Research Group
University of Pittsburgh-Pittsburgh campusPeter Wipf · Distinguished University Professor of Chemistry
Can novel synthetic and medicinal-chemistry methods yield small molecules that modulate challenging biological targets? The Wipf Group pursues total synthesis, strain-release and heterocyclic chemistry to access diverse scaffolds for biological testing. Medicinal-chemistry and structure–activity studies optimize small molecules as inhibitors or modulators of protein targets, including p97/VCP and PTP4A3, with the goal of generating probes and therapeutic leads. Collaborative translational projects apply these compounds in cancer, neurodegeneration, and radiation-mitigation studies.
Regina Barzilay Research Group
Massachusetts Institute of TechnologyRegina Barzilay · School of Engineering Distinguished Professor for AI and Health
Can machine learning detect cancer risk from routine clinical imaging before symptoms appear to enable earlier intervention? The group develops deep-learning models for personalized mammography-based risk prediction and early cancer detection. Researchers build ML methods for de-novo molecular design and retrosynthesis to change traditional drug-discovery pipelines toward data-driven generation. The team develops generative models such as BoltzGen to create protein binders for biological targets and tools like VaxSeer to predict virus evolution for vaccine strain selection. They also focus on interpretability and robustness for clinical AI to support safer, fairer deployment in healthcare settings.
Scott Gary Franzblau Research Group
University of Illinois ChicagoScott Gary Franzblau · Albert Schatz Professor of Medicinal Chemistry and Pharmacognosy
How can new drugs for tuberculosis be found by the Institute for Tuberculosis Research led by Scott Gary Franzblau? Scott Gary Franzblau is the Director of the Institute for Tuberculosis Research and the Albert Schatz Professor of Medicinal Chemistry and Pharmacognosy. The institute pursues large scale screening of both natural and synthetic compounds for those that demonstrate specificity of activity. Lead compounds are then optimized by semi-synthesis. Activity of all lead compounds is assessed in macrophage and mouse models of TB.
Shih‐Yuan Liu Research Group
Boston CollegeShih‐Yuan Liu · Professor of Chemistry
How can boron-nitrogen-containing heterocycles, specifically azaborines, be developed? Shih-Yuan Liu is engaged in synthetic chemistry with emphasis on developing molecules of importance in biomedical research and materials science. Azaborines are structures resulting from the replacement of two carbon atoms in benzene with a boron and a nitrogen atom. Azaborines are isosteres of the important family of benzenoid compounds, or arenes. Areas of exploration include organic synthesis, catalysis, hydrogen storage, optoelectronic materials, and drug discovery.
Stephen W. Fesik Research Group
Vanderbilt UniversityStephen W. Fesik · Professor of Biochemistry, Pharmacology, and Chemistry
Can fragment-based methods and structure-based design be used to find drugs for hard-to-drug cancer targets? Stephen Fesik is a Professor of Biochemistry, Pharmacology and Chemistry who holds the Orrin H. Ingram II Chair in Cancer Research. The Fesik lab uses fragment-based methods to identify small molecules, called fragments, that bind to difficult targets and structure-based design to optimize them for binding to the target protein. Current projects include discovery of KRAS inhibitors, WDR5 inhibitors and MYC/MAX inhibitors. The lab also works on the development of new NMR methods for fragment screening.
Ulrich Bierbach Research Group
Wake Forest UniversityUlrich Bierbach · Professor
Bierbach designs drug candidates that combine organic molecules with metal-based chemistry. His laboratory investigates platinum-acridine hybrid anticancer agents, linking chemical structure with biological activity and mechanisms of action. Research listed by Wake Forest includes identifying DNA targets, examining how membrane transport influences activity, and studying relationships between gene expression and drug sensitivity. The group also explores delivery formulations, including liposomal approaches. This is a preclinical research setting for people interested in medicinal and inorganic chemistry, where synthesizing a compound is paired with investigating how it reaches and affects cancer cells.
Yonghui Wu Research Group
University of FloridaYonghui Wu · Professor & Chief Data Scientist
How can natural language processing and large language models improve medical discovery and healthcare? Yonghui Wu is a Professor with Tenure in the Department of Health Outcomes & Biomedical Informatics, College of Medicine at the University of Florida. He is also the Chief Data Scientist & Director of Natural Language Processing (NLP) at the UF Clinical and Translational Science Institute (CTSI). His research interests include NLP, large language models (LLMs), Agentic Artificial Intelligence (AI), machine learning, and computational drug discovery using electronic health records (EHRs). He has a strong track record of building AI models and informatics tools to advance medical discovery and healthcare.
Zhong-Yin Zhang Research Group
Purdue University West LafayetteZhong-Yin Zhang · Distinguished Professor of Medicinal Chemistry
How can protein tyrosine phosphatases be targeted to control disease progression? The research spans chemistry and biology with an emphasis on protein tyrosine phosphatases (PTPs), enzymes that regulate cellular processes. These enzymes remove phosphoryl groups from tyrosine phosphorylated proteins. Abnormal PTP activity leads to aberrant cellular signaling linked to the development of cancer, diabetes and obesity, neurodegenerative and autoimmune disorders, and infectious diseases. Zhong-Yin Zhang is also Director of the Purdue Institute for Drug Discovery.
Showing 1–14 of 14 labs